Memcine Pharmaceuticals is categorized under Research and Development Laboratories in Iowa City, IA and active since 2010.
Memcine Pharmaceuticals was established in 2010, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Research and Development Laboratories business, which does work in the B2B market, and is classified as a Research and Development Laboratories, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Tony Vanden Bush at the company’s single location by writing to 2208 Arizona Avenue, Iowa City, Iowa IA 52240 or by phoning (319) 471-7803. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Memcine Pharmaceuticals |
| Contact Person: | Tony Vanden Bush |
| Address: | 2208 Arizona Avenue, Iowa City, Iowa 52240 |
| Phone Number: | (319) 471-7803 |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2010 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research and Development Laboratories |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Memcine Pharmaceuticals was started in 2010 to provide professional Research and Development Laboratories under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Tony Vanden Bush for inquiries that concern Memcine Pharmaceuticals by calling the company number (319) 471-7803, as your correspondence is most welcome. Additionally, the physical location of the single location of Memcine Pharmaceuticals can be found at the coordinates 41.636504,-91.502741 as well as the street address 2208 Arizona Avenue in Iowa City, Iowa 52240.
For its online presence, you may visit Memcine Pharmaceuticals’s website at and engage with its social media outlets through on Twitter and on Facebook.